Abbott’s breakthrough viral load testing product brings fast, accurate results in remote areas.

Innovative HIV Test Can Help Save Lives

Jul 24 2018

Imagine a woman living with HIV walking 10 kilometers in intense heat to get to a health clinic to take a test that measures the amount of HIV in her body. Then she has to walk back the same distance again a few weeks later to get her test results. Think about the physical hardships of her journey. Imagine the emotional and mental strain as she travels to find out whether her HIV treatment has been successful.

This is the plight of millions of people living with HIV in resource-limited areas of sub-Saharan Africa, Asia and Latin America.

However, this no longer needs to be the case.

Abbott’s newest solution, the m-PIMA™ HIV-1/2 VL is the first viral load monitoring test at the point of care. It has been designed to provide healthcare professionals – especially in remote and underserved communities – with a fast, accurate, and easy-to-use test to help manage their patients’ HIV.

The m-PIMA™ HIV-1/2 VL test joins Abbott’s broad portfolio of HIV diagnostic solutions that span the entire continuum of care for people at risk of and living with HIV. Diagnostics are a vital component of a holistic effort to achieve the UNAIDS 90-90-90 Goals and end the AIDS epidemic by 2030.

"The integration of point-of-care viral load solutions in healthcare networks will be instrumental in achieving UNAIDS’ 90-90-90 goals," said Professor Matilu Mwau, Director at the Center for Infectious and Parasitic Diseases Control Research, Kenya Medical Research Institute (KEMRI) in Busia, Kenya. "Viral load testing is critical for the monitoring of individual treatment response, the effective use of costly antiretroviral medications, and to track the emergence of resistance in people who are HIV-positive."1

Portable and robust, the m-PIMA platform can help address issues around infrastructure obstacles, shortage of skilled clinicians, logistical challenges and inefficient systems for providing results to patients.

The m-PIMA HIV-1/2 VL test is now commercially available in select countries. Data has been submitted for CE-IVD marking and WHO prequalification. This product is not available in the United States.

1 UNAIDS (2014) 90-90-90 An ambitious target to help end the AIDS epidemic. Available on





You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?


You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?